Annamycin Arms Show 43% and 36% Remission vs 12% Placebo in Pivotal AML Trial
MBRX has more than doubled off its 52-week low of $3.228 on light trading volume (0.1× avg).
Summary
First interim look at the pivotal Phase 2/3 AML trial shows complete remission rates of 43% and 36% in the two Annamycin arms versus 12% on placebo across the first 45 randomized patients. The Data Monitoring Committee recommended the study continue without amendment, so all three arms stay intact. No cardiac toxicity signs appeared through the data cutoff, notable for an anthracycline-class drug where cardiotoxicity is the main limitation. This is an early readout, not a completed efficacy confirmation, and the sample is small. The next data point is the second interim analysis expected in early 2027, which will include independent expert review of the cardiac safety data. Context: the company completed Part A enrollment of 89 subjects in late September and carries going-concern doubts plus a Nasdaq minimum-bid problem that a 1-for-20 reverse split effective October 20 was meant to address.
At the time of this announcement, MBRX was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $3.23 to $253.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.